The prevalence of programmed death protein ligand-1 (PD-L1) expression in NSCLC tissues ranges from 24% to 60%, and tumor PD-L1 expression appears to be a potential biomarker for predicting the effectiveness of immune checkpoint inhibitors (ICIs). This evidence concerns the gene CD274 and neoplasm.